• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Radiofrequency Ablation vs Stereotactic Body Radiotherapy for Recurrent HCC

byDaniel GoldshteinandSze Wah Samuel Chan
December 23, 2024
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Local progression-free survival at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group, with HR 0.45 (significant).

2. HR for progression-free survival (HR 0.76) and overall survival (HR 0.91) was nonsignificant.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Radiofrequency ablation (RFA), an effective and routine treatment for both primary and recurrent hepatocellular carcinoma (HCC), has prompted the exploration of alternatives like stereotactic body radiotherapy (SBRT), which delivers precise high-dose radiation with minimal impact on surrounding tissues. Retrospective studies suggest SBRT offers outcomes comparable to RFA. This study was the first randomized trial assessing RFA vs SBRT for recurrent HCC. The primary endpoint was local progression-free survival (LPFS) and secondary endpoints included progression-free survival (PFS), overall survival (OS), local control rate (LCR), and safety. LPFS at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group. It was found that the HR for LPFS was HR 0.45 (significant). It was found that SBRT performed better than RFA in LPFS for tumours ≤2 cm (HR 0.39, significant), however, this was not significant for larger (2-5 cm) tumours (HR 0.58, non-significant). LCR at 3 years was 92.8% for SBRT vs 75.9% for RFA with a 3-year OR 0.25 (significant). Median PFS time was 37.6 months for SBRT vs 27.6 months for RFA, with HR 0.76 (non-significant). OS at 3 years was 90.3% for SBRT vs 91.0% for RFA, with HR 0.91 (non-significant). Regarding safety, most adverse events were grade 1-2 with only 1 case of grade 3-4 events in each arm, a pneumothorax in the RFA group and thrombocytopenia in the SBRT group. The strengths of this study included the methodology, and the limitations included the small sample size. Overall, this study found that SBRT has some improved minor outcomes compared to RFA in treating adults with small recurrent HCC.

Click to read the study in JCO

Relevant Reading: Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma

RELATED REPORTS

Durvalumab and bevacizumab plus chemoembolization improves progression-free survival in hepatocellular carcinoma

Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma

#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer

In-Depth [randomized controlled trial]: This open-label single institution trial was conducted in China and enrolled adults with recurrent small (<5cm) HCC and randomized them (1:1) to either SBRT (n=83) or RFA (n=83). Most patients (88%) had hepatitis B virus (HBV)–related HCC. Some patients received a secondary RFA if residual disease was found after the first RFA. The median radiation dose of the SBRT group was 45 Gy (IQR, 42-48) in three fractions. Median follow-up time was 42.8 (95%CI, 39.8-45.8) months in the SBRT group and 42.9 (95%CI, 40.7-45.1) months in the RFA group. LPFS at 3 years was 84.3% (95%CI, 76.5-93.0) in the SBRT group vs 67.3% (95%CI, 57.6-78.6) in the RFA group. It was found that the HR for LPFS was HR 0.45 (95%CI, 0.24-0.87, p=0.014). It was found that SBRT performed better than RFA in LPFS for tumours ≤2 cm (HR 0.39, 95%CI, 0.17-0.89, p=0.020), however, this was not significant for larger (2-5 cm) tumours (HR 0.58, 95%CI, 0.20-1.68, p=0.310). LCR at 3 years was 92.8% for SBRT vs 75.9% for RFA with a 3-year OR 0.25 (95%CI, 0.09-0.65, p=0.005). Median PFS time was 37.6 (95%CI, 26.0-49.2) months for SBRT vs 27.6 (95%CI, 20.3-34.8) months for RFA, with HR 0.76 (95%CI, 0.50-1.15, p=0.190). OS at 3 years was 90.3% (95%CI, 83.7-97.5) for SBRT vs 91.0% (95%CI, 84.8-97.6) for RFA, with HR 0.91 (95%CI, 0.37-2.22, p=0.830). With regards to safety, most adverse events were grade 1-2 with only 1 case of grade 3-4 events in each arm, a pneumothorax in the RFA group and thrombocytopenia in the SBRT group. Overall, this study found that SBRT has some improved minor outcomes compared to RFA in treating adults with small recurrent HCC.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hccRFASBRT
Previous Post

#VisualAbstract: Tezepelumab Does Not Reduce Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Next Post

Therapeutic-dose anticoagulation reduces mortality risk compared with prophylactic-dose anticoagulation in patients hospitalized for COVID-19

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
Chronic Disease

Durvalumab and bevacizumab plus chemoembolization improves progression-free survival in hepatocellular carcinoma

March 13, 2025
VEGFR-targeted ultrasound may improve detection of pancreatic cancer
Chronic Disease

Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma

August 19, 2024
#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer
StudyGraphics

#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer

February 20, 2024
Many lung cancers visible on prior imaging studies
Chronic Disease

Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer

February 14, 2024
Next Post
siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]

Therapeutic-dose anticoagulation reduces mortality risk compared with prophylactic-dose anticoagulation in patients hospitalized for COVID-19

Increased risk of stillbirth recurrence after a previous stillbirth

Heated mittens not found to improve physical hand function in patients with osteoarthritis

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery
  • 2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]
  • Second-line TAF-based ART improves viral suppression in pediatric HIV
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.